

**Anti-Complement component C5a/C5a(desArg) anaphylatoxin (human)
Mouse monoclonal**

Subclass: IgG1/k

CAT. NO.

GAU 025-05

Clone: C17/5

SPECIFICITY	GAU 025-05 reacts with human C5a/C5a(desArg).
IMMUNOGEN	Purified human C5a
TESTED APPLICATIONS	ELISA, WB
SPECIES REACTIVITY (POSITIVE)	Human, baboon
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	GAU 025-05 binds to a neoepitope exposed on C5a/C5a(desArg) (1).

PRESENTATION

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION	ELISA: GAU 025-05 reacts well with C5a/C5a(desArg). A strong reaction is seen in ELISA with recombinant C5a coated onto the microtiter well (1). WB: GAU 025-05 can be used in Western blotting (1).
TARGET	Complement C5a is generated in the circulation by the activation of complement. It is a so-called anaphylatoxin of 74 amino-acid residues generated by the action of C5 convertase, which cleaves C5 into C5a and C5b. It is rapidly inactivated by serum carboxypeptidase B, which removes the C-terminal arginine residue generating C5a(desArg) (1).
REFERENCES	1. Oppermann M, Schulze M, Götze O (1991) A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm. 8:13-24.

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.